NLRP3 and Parkinson disease: In vivo, microinjection of the caspase‐1 inhibitor Ac‐YVAD‐CMK was shown to reduce the expression of NLRP3 inflammasome signaling proteins and improve the number of dopaminergic neurons in LPS‐induced and 6‐hydroxydopamine‐induced PD in rats (Mao et al, 2017).